DUBLIN--(BUSINESS WIRE)--The "Global Anti-viral Drug Market - Forecasts from 2020 to 2025" report has been added to ResearchAndMarkets.com's offering.
The Global anti-viral drug market was valued at US$59.068 billion in 2019.
Anti-viral drugs are used for treating influenza. The anti-viral drugs are used when it's just the start of flu illness, it can help in reducing fever and flu symptoms like cough, sore throat, runny or stuffy nose, body aches, headache, chills, and fatigue. The global anti-viral drug market is increasing due to the increasing prevalence of influenza across various countries around the world. The growing geriatric population and increasing government initiatives are also the driving factors for anti-viral drugs. The increasing geriatric population, according to the World Bank Data, rose from 7.49% of the total population in the world in the year 2009 to 8.87% of the total world population in the year 2018 of people aged 65 and above.
The increase in people aged 65 and above is due to improved health facilities around the world and people living a better lifestyle that includes better food quality and other facilities required for living. The improvement in medication and drugs is also a factor for the geriatric population. This is further increasing the demand for anti-viral drugs. The increasing influenza prevalence around the world is a second major reason for the increasing demand for anti-viral drugs around the world. According to the World Health Organization (WHO), North America saw a rise in influenza activity with a majority of people infected with influenza A viruses, with at least 80% of adult influenza-associated hospitalizations associated with influenza A viruses. The growing number of influenza cases in the United States is growing the requirement of an anti-viral drug in the country.
The growing adoption of vaccines around the world for providing better health services and preventing the spread of flu around the world and causing a pandemic is making the government increase their efforts in spreading the importance of vaccines. This will reduce the growth of anti-viral drugs. This is a major restricting factor for the anti-viral drug market. The market of anti-viral drugs is also restricted by the high cost incurred in the development of drugs and is increasing their prices, making it difficult for people to afford. This is further leading to the growth of alternatives like naturopathy and homeopathy, which will further restraint the anti-viral drug market.
The global anti-viral drug market is segmented by application type, mechanism of action, and by geography. On the basis of application type, the global anti-viral drug market is segmented by herpes antiviral drugs, hepatitis antiviral drugs, HIV antiviral drugs, influenza antiviral drugs, and other antiviral drugs. The global anti-viral drug market segmentation based on the mechanism of action is done by nucleotide polymerase inhibitors, reverse transcriptase inhibitors, protease inhibitors, and others.
- F. Hoffmann-La Roche Ltd
- Gilead Sciences, Inc.
- GlaxoSmithKline plc.
- Bristol-Myers Squibb Company
- Pfizer Inc.
- Abbott Laboratories
- AstraZeneca plc.
- AbbVie Inc.
- Johnson & Johnson
- Merck & Co., Inc.
- March 2020:- The WHO announced that Gilead's drug Remdesivir is showing signs that the drug may be able help treat the novel Coronavirus.
- December 2019: - Merck acquired ArQule, making ArQule a wholly-owned subsidiary of Merck. Merck, a leading global biopharmaceutical company known as MSD outside of the United States and Canada, has been inventing for life, bringing forward medicines and vaccines for many of the world's most challenging diseases.
- December 2019: - Roche concluded the acquisition of Spark Therapeutics, Inc. for strengthening presence in gene therapy. The Spark to continue its operations in Philadelphia as an independent company within the Roche Group. The companies together will improve the lives of the patients through innovative gene therapies. Spark Therapeutics, based in Philadelphia, Pennsylvania, is a fully integrated, commercial company committed to discovering, developing and delivering gene therapies for genetic diseases, including blindness, hemophilia, lysosomal storage disorders, and neurodegenerative diseases.
Key Topics Covered:
2. Research Methodology
3. Executive Summary
4. Market Dynamics
4.1. Market Drivers
4.2. Market Restraints
4.3. Porters Five Forces Analysis
4.4. Product Pipeline
4.5. Industry Value Chain Analysis
5. Global Anti-Viral Drug Market Analysis, By Application Type
5.2. Herpes Antiviral Drugs
5.3. Hepatitis Antiviral Drugs
5.4. HIV Antiviral Drugs
5.5. Influenza Antiviral Drugs
5.6. Other Antiviral Drugs
6. Global Anti-Viral Drug Market Analysis, By Mechanism of Action
6.2. Nucleotide Polymerase Inhibitors
6.3. Reverse Transcriptase Inhibitors
6.4. Protease Inhibitors
7. Global Anti-Viral Drug Market Analysis, By Geography
7.2. North America
7.3. South America
7.5. Middle East and Africa
7.6. Asia Pacific
8. Competitive Environment and Analysis
8.1. Major Players and Strategy Analysis
8.2. Emerging Players and Market Lucrativeness
8.3. Mergers, Acquisitions, Agreements, and Collaborations
8.4. Vendor Competitiveness Matrix
9. Company Profiles
For more information about this report visit https://www.researchandmarkets.com/r/bs6aqj